Canrenone as Add-on in Patients With Essential Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

Also called NCT02687178

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 180 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02687178
Other papers using this trial's data
  • Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial Cardiovascular therapeutics, 2017-02 DOI, PubMed 27860389, PMC6680336 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02687178. Randomized; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2015-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Canrenone as Add-on in Patients With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
Canrenone 50 vs canrenone 100 mg
Lead sponsor
University of Pavia (class: other)

Record details

Record id
cardio:ct-nct02687178
Content hash
96e61fdabad4c620d40bcdb79eb7673ad6244a9ce866e81f101cacc5f960e774